Select Publications

1. Magnusson C et al. Breast cancer risk following long-term oestrogen and oestrogen-progestin replacement therapy. Int J Cancer 1999; 81(3):339-44. Abstract

2. Schairer C et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA2000;283(4):485-91. Abstract

3. Ross RK et al. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92(4):328-32. Abstract

4. Hofseth LJ et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84(12):4559-65. Abstract

5. Greendale GA et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130(4 Pt 1):262-9. Abstract

6. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-1059. Abstract

7. Lundstrom E et al. Mammographic breast density during hormone replacement therapy: Effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001;4(1):42-8. Abstract

8. Pike MC, Ross RK. Progestins and menopause: Epidemiological studies of risks of endometrial and breast cancer. Steroids2000; 65(10-11):659-64. Abstract

9. Sterns EE, Zee B. Mammographic density changes in perimenopausal and postmenopausal women: Is effect of hormone replacement therapy predictable? Breast Cancer ResTreat 2000;59(2):125-32. Abstract

10. Ettinger B et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994;83(5 Pt 1):693-700. Abstract

11. Williams DB et al. Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol 1994;84(5):787-93. Abstract

12. Shoupe D et al. Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone. N Engl J Med 1991; 325(25):18 11-2. No abstract available.

13. Colditz GA. Estrogen replacement therapy for breast cancer patients. Oncology (Huntingt) 1997;11(10):1491-4,1497; discussion 1498, 1501. Abstract

14. Fisher B et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371-88. Abstract

15. Ganz PA. Menopause and breast cancer: Symptoms, late effects and their management. Semin Oncol 2001;28(3):274-83. Abstract

16. Jacobs HS. Hormone replacement therapy and breast cancer. Endocr Relat Cancer 2000;7(1):53-61. Full-Text

17. Marsden J et al. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 2000;73(2):292-9. Abstract

18. Chlebowski RT, McTiernan A. Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol 1999;17(1):130-42. Abstract

19. Col NF et al. Hormone replacement therapy after breast cancer: A systematic review and quantitative assessment of risk. J Clin Oncol 2001;19(8):2357-63. Abstract

20. McCarty MF. Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity. Med Hypotheses 2001;56(2):213-6. Abstract

21. O'Meara ES et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93(10):754-62. Abstract

22. Pritchard KI. Hormone replacement in women with a history of breast cancer. Oncologist 2001;6(4):353-62. Abstract

Home · Search